0.8921

11.32% 0.102

Jasper Therapeutics Inc (JSPR)

Overview News Price History Option Chain Financials Discussions Forecast

Jasper Therapeutics Inc stock is traded at $0.8921, with a volume of 498.96K. It is up +11.32% in the last 24 hours and down -0.62% over the past month. Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Previous Close:

$0.7901

Open:

$0.77

24h Volume:

498.96K

Relative Volume:

0.44

Market Cap:

$28.87M

Revenue:

Net Income/Loss:

$-55.73M

P/E Ratio:

-0.2764

EPS:

-3.2274

Net Cash Flow:

$-68.87M

1W Performance:

+10.02%

1M Performance:

-0.62%

6M Performance:

-27.31%

1Y Performance:

-71.72%

1-Day Range:

$0.7455

$0.8795

1-Week Range:

$0.7455

$0.97

52-Week Range:

$0.3151

$3.13

Jasper Therapeutics Inc Stock (JSPR) Company Profile

Name

Jasper Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(650) 549-1400

Address

2200 BRIDGE PKWY SUITE #102, REDWOOD CITY

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

JSPR's Discussions on Twitter

Compare JSPR vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JSPR Jasper Therapeutics Inc	0.8675	26.29M	0	-55.73M	-68.87M	-3.2274
VRTX Vertex Pharmaceuticals Inc	516.25	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.82	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.77	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.15	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.23	39.31B	5.76B	514.49M	1.10B	4.4813

Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Resumed	UBS	Neutral
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Jul-08-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-07-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-13-25	Initiated	UBS	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Sep-09-24	Initiated	JMP Securities	Mkt Outperform
Jul-08-24	Initiated	BTIG Research	Buy
Jun-27-24	Initiated	Stifel	Buy
May-06-24	Initiated	H.C. Wainwright	Buy
Apr-03-24	Initiated	Evercore ISI	Outperform
Mar-28-24	Initiated	RBC Capital Mkts	Outperform
Mar-18-24	Initiated	TD Cowen	Outperform
Aug-11-23	Initiated	CapitalOne	Overweight
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight
Nov-08-21	Initiated	Credit Suisse	Outperform
Oct-21-21	Initiated	William Blair	Outperform
Oct-20-21	Initiated	BMO Capital Markets	Outperform
Oct-13-21	Initiated	Oppenheimer	Outperform

View All

Jasper Therapeutics Inc Stock (JSPR) Latest News

08:30 AM

Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance

08:30 AM

07:03 AM

Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com South Africa

07:03 AM

06:47 AM

Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com

06:47 AM

06:33 AM

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com

06:33 AM

Aug 14, 2026

Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade

Aug 14, 2026

Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan

Aug 14, 2026

Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 14, 2026